Affimed N.V. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AFMD Nasdaq 2836 www.affimed.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Affimed N.V.

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) - Dec 9th, 2024 6:30 pm
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer - Dec 9th, 2024 11:30 am
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients - Dec 8th, 2024 5:00 pm
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy - Dec 6th, 2024 3:36 pm
FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy - Dec 6th, 2024 9:26 am
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA) - Dec 5th, 2024 11:30 am
Is Affimed N.V. (AFMD) the Best German Stock to Buy Now? - Nov 19th, 2024 11:33 pm
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... - Nov 15th, 2024 7:10 am
Affimed N.V.: Q3 Earnings Snapshot - Nov 14th, 2024 11:38 am
Affimed Reports Third Quarter 2024 Financial Results & Business Update - Nov 14th, 2024 11:30 am
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024 - Nov 6th, 2024 11:30 am
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates - Nov 5th, 2024 10:15 pm
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma - Nov 5th, 2024 2:00 pm
683 Capital Management, LLC Expands Stake in Affimed NV - Oct 24th, 2024 9:01 pm
Affimed to Present at the Cantor Global Healthcare Conference 2024 - Sep 10th, 2024 10:30 am
Affimed N.V.: Q2 Earnings Snapshot - Sep 5th, 2024 10:46 am
Affimed Reports Second Quarter 2024 Financial Results & Business Update - Sep 5th, 2024 10:30 am
Affimed Appoints New CEO, Shares Fall on Leadership Change - Sep 4th, 2024 3:26 pm
Affimed Appoints Shawn M. Leland as Chief Executive Officer - Sep 3rd, 2024 11:45 am
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024 - Aug 29th, 2024 10:30 am